Prostate cancer is one of the major health problems in the world (
1), has a significant impact on patients’ and their caregivers’ quality of life, and imposes heavy costs on them (
2). It is the second most common cancer and the second leading cause of death from cancer among the male population worldwide (
3,
4). The peak incidence of disease is in people between the ages of 60 and 70 (
2). The incidence of prostate cancer in developed countries is six times higher than in less developed countries (
5). Although not many studies on prostate cancer are conducted in Asia, including Iran, it continues to be one of the main causes of death in Iran (
6). According to the cancer statistical center of Iran, in 2009 prostate cancer had an age-standardized incidence rate (ASR) of 12.59 per 100,00 people, making it the third most prevalent cancer among men in Iran (
7). In Khuzestan province, prostate cancer also ranked as the third most common cancer among men, and accounts for about 8% of all cancers in this region. The reported ASR in this region is 7.64 per 100,000 people (
8).
The causes of prostate cancer are not completely understood, but it is believed that aging, positive family history, and race (e.g. African-American race) are among the relevant risk factors (
9). The nature of prostate cancer is such that as long as there is no local progression or metastasis to other parts of the body, it usually does not cause any symptoms (
10), and on presentation of symptoms, the disease usually has run its course. Therefore, early detection of the disease in its early stages can be an effective measure in reducing its mortality rate in asymptomatic men (
11,
12), and creates an opportunity to use effective and inexpensive treatment methods (
13). The detection phase is an important factor in the expression of the cancer-related survival rate. The five-year survival rate in men with localized (i.e., without metastasis) prostate cancer is almost 100%, while the rate among men with prostate cancer that has metastasized to other parts of the body is only 31% (
11).
Expansion of prostate cancer screening programs will certainly lead to increased diagnosis in the early stages, and therefore to treatment (
12). The effectiveness of prostate cancer screening methods to identify the disease and reduce mortality from it has been proven, as various studies have shown reduced mortality from prostate cancer through screening programs (
14). Early detection and screening of prostate cancer are done using a prostate antigen serum (PSA) test and a rectal examination (DRE) (
12). Prostate antigen is a serine protease that is produced by the prostate epithelial cells and can be found in the blood serum. In a rectal examination, the approximate size of the prostate is determined and any abnormal growths can be detected (
15). In an analysis of data collected from seven European countries, a significant reduction in mortality from prostate cancer following a PSA test was observed after a period of about nine years (
16); in addition, a study by Hugosson et al. in 2010 (
17) suggests a decrease in mortality rate following prostate cancer screening tests.
Despite the importance of early detection in increasing life expectancy, the results of the studies suggest that men are not willing to take screening test procedures. These include studies of Filipino men living in Hawaii, African-American men, and men living in the Caribbean; the results indicate low participation of these groups in screening programs, even though their incidence of prostate cancer is relatively high (
11,
18). In addition, men with few symptoms are usually not willing to see a doctor, and see the doctor only when their condition becomes severe (
19). The reason for low participation in the screening program is still not quite clear, but it may be associated with low socio-economic status, lack of insurance coverage for screening, lack of knowledge about prostate cancer, and lack of physician recommendations for screening (
20-
23).
There are differences in the recommended time for prostate cancer screening. The American urological association has recommended prostate cancer screening for men 40 years or older with a life expectancy of at least 10 years (
24), while the United States prostate cancer foundation (PCF) has recommended screening for men over 50 years with a life expectancy of at least 10 years (
11). The preventive services task force of America (USPSTF) has stated that screening in people 75 years and older should not be performed due to the higher risks and lower benefits of screening (
25). Therefore, men aged between 40 and 75 years are the most suitable target group for prostate cancer screening.
According to the above-mentioned studies, understanding people’s knowledge of a disease and why so many at-risk people ignore screening behaviors is very important. Several different models have identified relevant factors. One of these models is the health belief model (HBM), which is designed to understand why people who are at risk of a disease are not willing to take diagnostic procedures (
26). The model consists of six constructs affecting health behaviors, including perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, and cues to action (
27). In this study, the construct of perceived barriers is used to identify barriers associated with screening behavior.
HBM been used as a predictor of behavior in diseases such as skin cancer (
28), colorectal cancer (
29), breast cancer (
30), and cervical cancer (
31) in different countries. This model was used in Iran for some cancers such as breast cancer (
32), cervical cancer (
33), and colorectal cancer (
34), and all the studies emphasized the importance of applying the model in predicting behaviors.